HLA-A*02:01 in uveal melanoma

1 EU-approved indication in uveal melanoma needs a HLA-A*02:01 result: tebentafusp (advanced).

Line of therapy

Approved indications, Uveal melanoma
DrugBiomarker requirementRegimenSettingConditions
HLA-A*02:01-positive1
Tebentafusp
Kimmtrak
Monotherapy
Any line
advanced
None

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Tebentafusp (Kimmtrak)
    KIMMTRAK is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.